H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026

On March 10, 2026 H.C. Wainwright maintained a Buy on Capricor Therapeutics, Inc. (CAPR), a clear signal for investors watching small-cap biotech. The CAPR analyst rating remained a Buy with a $60 price target cited in market coverage. We note this action came as the stock moved -4.49% (-$1.57) since the firm’s last commentary. This maintained rating keeps H.C. Wainwright as the primary active analyst covering CAPR

What the CAPR analyst rating means for investors

A maintained Buy means H.C. Wainwright still expects upside versus current market levels. For investors, the CAPR analyst rating signals confidence in Capricor’s development roadmap and value drivers, but it is not a guarantee of price gains.

Analyst action and timeline

On March 10, 2026 H.C. Wainwright reiterated Buy in a note reported by StreetInsider and Investing.com. The firm kept its $60 price target, per Investing.com source and the StreetInsider release confirms the reiteration source.

CAPR analyst rating and price target context

The $60 price target reflects H.C. Wainwright’s model assumptions on trial readouts and potential commercial pathways. That target is materially above recent market prices, and it frames the maintained Buy as a forward-looking endorsement rather than a comment on near-term volatility.

Market reaction and stock performance

Since the note, Capricor’s stock moved -4.49% (-$1.57) in the reported window, showing short-term sensitivity to biotech headlines. The maintained CAPR analyst rating did not spark an immediate rally, indicating investors may be waiting for clinical or regulatory catalysts.

Historical analyst coverage and significance

Coverage of Capricor has been concentrated and sporadic, with H.C. Wainwright one of the few consistent firms. That limited analyst universe means each CAPR analyst rating carries more weight than it might for larger, widely covered names.

Meyka AI grade and how we view the rating

Meyka AI rates CAPR with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. As an AI-powered market analysis platform, Meyka AI flags the maintained Buy as supportive but notes concentrated coverage risk.

Final Thoughts

H.C. Wainwright’s decision on March 10, 2026 to maintain a Buy on Capricor Therapeutics, Inc. (CAPR) and its $60 price target keeps a positive analyst tilt on the stock. The CAPR analyst rating suggests upside based on pipeline assumptions, but investors should weigh that view against the company’s event calendar and limited analyst coverage.

Practical takeaways: the maintained Buy is supportive but not decisive. The market’s -4.49% (-$1.57) move shows short-term sensitivity. We recommend investors use the CAPR analyst rating as one input among fundamentals, upcoming clinical milestones, and risk tolerance. Meyka AI rates CAPR with a grade of B+, which incorporates benchmark and sector performance metrics and should not be taken as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.